| |
Tumour volume (% of day 0) at day 4 (N)
|
P compared to day 0
|
Tumour volume (% of control) at day 4)
|
P compared to Control at day 4
|
|---|
|
Control
|
128.4 ± 5.9 (11)
|
0.0007
| | |
|
17-AAG (20mg/kg)
|
88.5 ± 2.9 (11)
|
0.003
|
68.9%
|
<0.0001
|
|
17-AAG (40mg/kg)
|
67.0 ± 3.6 (10)
|
<0.0001
|
52.2%
|
<0.0001
|
|
17-AAG (80mg/kg)
|
42.1 ± 7 (6)
|
0.0004
|
32.8%
|
<0.0001
|
- Effect of 3 daily doses of 17-AAG (20mg/kg, 40mg/kg, 80mg/kg) or vehicle only (control) on tumour volume in MMTV-NEU-NT transgenic mice. Tumour volume expressed as a % of day 0 (column 2), p values: day 4 vs day 0. Tumour volume also expressed as a % of control cohort at day 4 (column 4), p values: treated day 4 vs control day 4. Mean tumour volume at day 0 of the 4 cohorts was 0.59 ± 0.08 cm3 (control), 0.67 ± 0.07 cm3 (20mg/kg), 0.67 ± 0.08 cm3 (40mg/kg) and 0.61 ± 0.12 cm3 (80mg/kg). Data are presented as the mean ± SEM.
